{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"116"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"29"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"14"},{"groupId":"OG017","value":"34"},{"groupId":"OG018","value":"5"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"57"},{"groupId":"OG021","value":"5"},{"groupId":"OG022","value":"5"}]}],"title":"TEAE's"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"59"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"14"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"4"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"7"},{"groupId":"OG017","value":"16"},{"groupId":"OG018","value":"3"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"31"},{"groupId":"OG021","value":"2"},{"groupId":"OG022","value":"1"}]}],"title":"SAE's"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"117"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"29"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"14"},{"groupId":"OG017","value":"34"},{"groupId":"OG018","value":"5"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"57"},{"groupId":"OG021","value":"5"},{"groupId":"OG022","value":"5"}],"units":"Participants"}],"description":"The number of participants who experienced treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) during the study.","groups":[{"description":"Participants received 0.08 or 0.1 mg of Pegilodecakin once daily (QD) administered subcutaneously (SC).\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG000","title":"Part A: Pegilodecakin 0.08/0.1 mg"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG001","title":"Part A: Pegilodecakin 0.2/0.25 mg"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG002","title":"Part A: Pegilodecakin 0.4/0.5 mg"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG003","title":"Part A: Pegilodecakin 0.8/1 mg"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG004","title":"Part A: Pegilodecakin 1.6/2 mg"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG005","title":"Part A: Pegilodecakin 3.2/4 mg"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG006","title":"Part B: Pegilodecakin 0.2/0.25 mg + Platinum/Taxane"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG007","title":"Part B: Pegilodecakin 0.4/0.5 mg + Platinum/Taxane"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG008","title":"Part B: Pegilodecakin 0.8/1 mg + Platinum/Taxane"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG009","title":"Part C: Pegilodecakin 0.2/0.25 mg + FOLFOX"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG010","title":"Part C: Pegilodecakin 0.4/0.5 mg + FOLFOX"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG011","title":"Part C: Pegilodecakin 0.8/1 mg + FOLFOX"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC with Gemcitabine 1000 mg/m2 IV over 30 minutes plus nab-paclitaxel 125 mg/m2 IV over 30 to 40 minutes on Days 1, 8, and 15 of every 28-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG012","title":"Part D: Pegilodecakin 0.4/ 0.5 mg + Gemcitabine/Nab-Paclitaxel"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Capecitabine 1000 mg/m² orally twice daily (BID) on Days 1 through 14 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG013","title":"Part E: Pegilodecakin 0.8/1 mg + Capecitabine"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Paclitaxel 80 mg/m2 IV over 3 hours on Days 1, 8, and 15 of every 28-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG014","title":"Part F: Pegilodecakin 0.8/ 1 mg + Paclitaxel"},{"description":"Participants received a 0.8 or 1 mg of Pegilodecakin QD administered SC with Pazopanib 800 mg orally QD.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG015","title":"Part G: Pegilodecakin 0.8/1 mg + Pazopanib"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG016","title":"Part H: Pegilodecakin 0.8/1 mg + Pembrolizumab"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG017","title":"Part H: Pegilodecakin 1.6/2 mg + Pembrolizumab"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG018","title":"Part H: Pegilodecakin 3.2/4 mg + Pembrolizumab"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Nivolumab 3 mg/kg IV infusion over 60 minutes on Day 1 of each 14-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG019","title":"Part I: Pegilodecakin 0.8/1 mg + Nivolumab"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC with Nivolumab 3 mg/kg IV infusion over 60 minutes on Day 1 of each 14-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG020","title":"Part I: Pegilodecakin 1.6/2 mg + Nivolumab"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC with gemcitabine 500 mg/m2 IV over 30 minutes followed by carboplatin targeting an AUC2 IV over 60 minutes on Days 1 and 8 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG021","title":"Part J: Pegilodecakin 0.4/0.5 mg + Gemcitabine/Carboplatin"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with gemcitabine 500 mg/m2 IV over 30 minutes followed by carboplatin targeting an AUC2 IV over 60 minutes on Days 1 and 8 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG022","title":"Part J: Pegilodecakin 0.8/1 mg + Gemcitabine/Carboplatin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of study intervention.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug through 30 days after the last dose of study drug (Up to 63 Months)","title":"Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin","type":"PRIMARY","unitOfMeasure":"Participants"}